Corvus Pharmaceuticals, Inc. announced that it has discontinued its Phase III study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalizations.
[Corvus Pharmaceuticals, Inc.]
6445212
nan
items
1
apa
0
default
asc
1
164673
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
